Prestige Consumer Healthcare (PBH) Cash from Investing Activities Growth (1y) (2011 - 2025)
Prestige Consumer Healthcare (PBH) Cash from Investing Activities Growth (1y) (2011 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 13.93% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 57.14% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -186.78% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 551.55% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 526.11% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | -3,664.79% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -3.45% |
| 10 | Prestige Consumer Healthcare | 2.41 Bn | 2.35 Bn | 157.37 Mn | -1,209.70% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1,209.70% |
| Sep 30, 2025 | -44.50% |
| Jun 30, 2025 | 9.01% |
| Mar 31, 2025 | 76.81% |
| Dec 31, 2024 | -118.33% |
| Sep 30, 2024 | 30.91% |
| Jun 30, 2024 | -191.69% |
| Mar 31, 2024 | -135.99% |
| Dec 31, 2023 | -149.36% |
| Sep 30, 2023 | -23.48% |
| Jun 30, 2023 | 321.87% |
| Mar 31, 2023 | -93.08% |
| Dec 31, 2022 | 91.09% |
| Sep 30, 2022 | 98.97% |
| Jun 30, 2022 | 20.86% |
| Mar 31, 2022 | 32.74% |
| Dec 31, 2021 | -253.16% |
| Sep 30, 2021 | -2,455.33% |
| Jun 30, 2021 | 48.18% |
| Mar 31, 2021 | 40.76% |